Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Hamburg, Germany and Baltimore, Maryland, 2019.09.04 ̶ Using Sysmex Inostics’ novel SafeSEQ next-

generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of

Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to

examine the use of a non-invasive liquid biopsy in early diagnosis of breast cancer. This study was

unique in that the ctDNA analyses was performed before any invasive diagnostic procedure or

treatment.

The SafeSEQ liquid biopsy technology has shown sensitivity down to five mutant molecules in a

background of ten thousand normal ones (or 0.05% mutant allele frequency also known as MAF).

Utilizing the genes TP53 and PIK3CA, which are commonly mutated in breast cancer, investigators

compared the results of traditional standard-of-care tissue biopsy with those of liquid biopsy to

determine the degree to which a highly sensitive assay might complement clinical assessment of

disease. Of the 13 mutations detected in 10 of the primary breast cancer patients (out of a total of 29

samples) 8 mutations had a variant allele frequency less than 0.39%.

Comparing tissue to liquid biopsy, eight patients had detectable mutations in ctDNA with concordant

results between tissue and plasma. Liquid biopsy testing with SafeSEQ detected an additional three

patients with ctDNA mutations that were not present in the tissue. The breast cancer samples with

detected ctDNA biomarkers were significantly associated with a lower patient age, a higher tumor size,

and higher imaging score (indicating higher likelihood of neoplastic disease).

“We have shown in this study how important a sensitive technology is for early detection of breast

cancer, as trace amounts of circulating tumor DNA may be lost by the detection method leading to false-

negative results”, said Dr. Emilio Alba, senior author of the Biomedical Research Institute of Malaga.

“Studies of this kind have not been attempted before due to limitations of the technology, and it is great

to see Sysmex Inostics leading the path forward for early detection.”

The publication “Detection of TP53 and PIK3CA mutations in circulating tumor DNA using Next-

Generation Sequencing in the screening process for early breast cancer diagnosis”, was published online

in the Journal of Clinical Medicine in August of 2019. https://doi.org/10.3390/jcm8081183

 

About Sysmex Inostics

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company that is a pioneer

in blood-based cell-free tumor DNA (ctDNA) mutation detection in oncology utilizing highly sensitive

technologies such as OncoBEAM™ (digital PCR) and SafeSEQ (NGS). These technologies were initially

developed by experts at the Johns Hopkins School of Medicine over a decade ago and this deep

expertise in ctDNA analysis extends to the core of Sysmex Inostics’ capabilities for technology

development and implementation.

With more than 10 years’ of experience in liquid biopsy, Sysmex Inostics is a trusted partner to leading

pharmaceutical companies, advancing their efforts to bring the most effective personalized cancer

therapies to global markets, from discovery through companion diagnostics.

Sysmex Inostics’ OncoBEAM™ and SafeSEQ services are readily available to support clinical trials and

research in oncology. In addition, OncoBEAM™ tests are available through a CLIA certified laboratory for

routine clinical analysis as well as distributed kit products in the EU and Asia Pacific.

Sysmex Inostics’ headquarters and GCP Service Laboratory are located in Hamburg Germany; Sysmex

Inostics’ CLIA-certified and GCP Clinical Laboratory is located in Baltimore, Maryland. For more

information refer to www.sysmex-inostics.com or email info@sysmex-inostics.com.

Contact:

Sysmex Inostics

Press Release

Phone: +49-(0)-40-3259070

Mail: info@sysmex-Inostics.com 

Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Cancer-News

1 month
24 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Up Next Autoplay
Lower Costs for Patients in Metastatic Breast Cancer
Lower Costs for Patients in Metastatic Breast Cancer
Category: Breast Cancer
1 Views
ONeal Comprehensive Cancer Center 3 hours
New Technology to Streamline Drug Discovery
New Technology to Streamline Drug Discovery
Category: Other
2 Views
Cancer-News 1 day
Using Technology to Better Understand What Goes Wrong in Cancer
Using Technology to Better Understand What Goes Wrong in Cancer
Category: Breast Cancer
1 Views
Cancer-News 1 day
How Does This Affect Clinicians Today?
How Does This Affect Clinicians Today?
Category: Breast Cancer
1 Views
Cancer-News 1 day
Measuring Chromatin Accessibility: How Reliable is This Data?
Measuring Chromatin Accessibility: How Reliable is This Data?
Category: Breast Cancer
1 Views
Cancer-News 1 day
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
3 Views
Cancer-News 1 day
Mapping the usual breast development to recognize cancer better
Mapping the usual breast development to recognize cancer better
Category: Breast Cancer
4 Views
Cancer-News 1 day
Metformin: How Does This Affect Treatment?
Metformin: How Does This Affect Treatment?
Category: Ovarian Cancer
5 Views
Cancer-News 1 day
New Frontier Possibility for Preventing Ovarian Cancer
New Frontier Possibility for Preventing Ovarian Cancer
Category: Ovarian Cancer
3 Views
Cancer-News 1 day
"Wild idea" opens possible new boundaries to ovarian cancer prevention
Category: Ovarian Cancer
5 Views
Cancer-News 1 day